Being reviewed and treated through medical oncology service at Royal Marsden Hospital
Cohort 1: Locally Advanced/Metastatic NSCLC
Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS), AND
Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent
Cohort 2: Locally Advanced/Metastatic GIST
Locally advanced/metastatic gastrointestinal stromal tumour (GIST), AND
Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent
Cohort 3: Metastatic Colorectal Cancer
Metastatic colorectal cancer, left sided, RAS wild type, HER2 any status, AND
If HER2 negative or unknown: progressive disease on systemic anti-cancer therapy (SACT) with an anti-EGFR agent (e.g. cetuximab) within the 6 weeks prior to consent
If HER2 positive: progressive disease on first line systemic anti-cancer therapy (SACT) +/- an anti-EGFR agent within the 6 weeks prior to consent
Cohort 4: Locally Advanced/Metastatic BTC
Identified targetable mutation (IDH1 mutation/HER2 amplification/FGFR2 fusion or rearrangement/NTRK fusion/BRAF V600E mutation/MMR deficiency \[dMMR\]), AND
Progressive disease on targeted therapy (any line) demonstrated within the 6 weeks prior to consent
Cohort 5: Advanced/Metastatic ovarian cancer
Diagnosis of advanced/metastatic high-grade ovarian cancer, AND
Known BRCA status, AND
Progressive disease on a PARP-inhibitor (with or without bevacizumab) following platinum-based therapy in the 1st line maintenance setting, within the 6 weeks prior to consent
You may not be if
All cohorts:
Medically unstable to commit to sampling required for the study
